2017 American Transplant Congress
A Novel Endpoint for Evaluating the Effect of Everolimus with Reduced Calcineurin Inhibitor on Long-Term Kidney Graft Outcome: The TRANSFORM Study Protocol.
1TRANSFORM Study Group, Murray; 2Novartis Pharma AG, Basel, Switzerland
Purpose: With the advancement of immunosuppressive (IS) agents, while short-term graft outcomes improved significantly, long-term outcomes remain a concern. Both acute rejection (AR) and nephrotoxicity…2017 American Transplant Congress
Patient Outcomes Following the Disappearance of Donor Specific Antibody in Crossmatch Positive Simultaneous Liver-Kidney Transplant Recipients.
Background: Simultaneous liver and kidney transplantation (SLKT) remains as the gold standard for patients with chronic renal and liver diseases. Pre-transplant donor-specific antibody (DSA) to…2017 American Transplant Congress
A Universal Strategy to Characterize Allograft Infiltrating Cells by Bioinformatics Deconvolution of Next Generation Sequencing Data.
1Weill Cornell Medicine-Qatar, Doha, Qatar; 2Weill Cornell Medicine, New York
RNA sequencing characterizes mRNA transcriptome at an unprecedented level of precision. Because organ transplantation is a unique situation of mRNAs encoded by two (donor and…2017 American Transplant Congress
Applicability and Safety of a Regulatory T Cell Therapy in Adult Liver Transplantation: The “ThRIL” Phase I First-in-Human Trial.
MRC Centre for Transplantation, King's College London, London, United Kingdom
Aim“ThRIL” is a multiple site, open-label, uncontrolled, phase I clinical trial assessing the safety and applicability of a CD4+CD25+FOXP3+ regulatory T cell (Treg) immunotherapy in…2017 American Transplant Congress
Glomerular CD45 Immunostaining in Post Perfusion Graft Biopsies Predicting Rejection.
Renal Transplant Unit, University Hospitals Coventry, Coventry, United Kingdom
Introduction: Recipients of incompatible renal allografts remain at risk of developing AMR after transplantation. Current microarray analysis of allograft biopsies showed similar disturbances in AMR…2017 American Transplant Congress
Specific Gene Expression Signature of Complement-Activating Donor Specific Anti-HLA Antibody-Mediated Rejection in Kidney Allografts.
Complement-binding anti-HLA DSA have demonstrated higher rejection rate and decreased allograft survival. However, their specific effects on rejection pathogenesis have not been identified. We investigated…2017 American Transplant Congress
Complement Binding Activity (C3d, C1q) of De Novo Donor-Specific HLA Antibody Is Associated with Increased Risk of Antibody-Mediated Rejection in Non-Sensitized Kidney Transplant Recipients.
Despite advances in therapeutic strategies and medicine, antibody mediated rejection (AMR) is a leading cause of kidney graft loss. The complement binding activity of donor-specific…2017 American Transplant Congress
Dual Treatment of Suboptimal Doses of CsA and MSC Infusion Fully Prevents Acute Rejection in an Allogenic Model of Renal Transplantation.
The immunomodulatory characteristics of mesenchymal stem cells (MSCs) may lead to multifaceted strategies in rejection of organ transplantation. This study was designed to investigate the…2017 American Transplant Congress
Is Thymic Function Determining Rejection Onset in Heart Transplantation?
The thymus is the primary site of T cell development, involuting into fatty tissue in adults. Thymic function persists in the adulthood and may be…2017 American Transplant Congress
Retrospective Analysis of Kidney Transplant Recipients with Antibody-Mediated Rejection.
Acute antibody mediated rejection (AMR) is a major cause of allograft loss.We retrospectively reviewed all kidney allograft recipients between 2002 and March 2016. Investigated the…
- « Previous Page
- 1
- …
- 108
- 109
- 110
- 111
- 112
- …
- 172
- Next Page »